CD4 and B-cell chronic lymphocytic leukemia: Results revealed that CLL-derived EVs: (i) contain miR-363 that targets the immunomodulatory molecule CD69 and (ii) alter the function of CD4+ T cells, promoting their proliferation, migration and immune synapse signalling, modifying the communication with the ME.